HGS, Xencor team up on antibody tech

In another display of monoclonal antibodies' appeal to drug developers, Maryland-based Humab Genome Sciences announced that it will team up with Xencor on drug development. Xencor uses its XmAb technologies--which humanizes antibodies--to enhance the pharmacologic properties of monoclonal antibodies developed by HGS that specifically target antigens discovered by HGS. Xencor gains an upfront payment and could earn additional payments including development and commercial milestones, and royalties. Further financial details were not disclosed. Xencor was a 2005 Fierce 15 company.

- see this release for more

Related Articles:
HGS stock dives on drug safety concerns. Report
Xencor adds $15M to fifth VC round. Report

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.